Thursday, June 20, 2024 JAK Inhibitor Surprisingly Enhances Effectiveness of Cancer Immunotherapy Colorized scanning electron micrograph of a macrophage, a type of myeloid cell. (Credit: NIAID) Research co-funded by NIAID found that a type of drug called a JAK inhibitor made a common form of cancer immunotherapy more effective in mouse models and in people with Hodgkin lymphoma who did not respond to treatment or relapsed. This is surprising because JAK inhibition usually suppresses immune responses. The researchers showed that a JAK inhibitor enhanced immunotherapy with immune checkpoint inhibitors only in the presence of a family of immune cells called myeloid cells. The combination treatment appeared to alter myeloid cells in immune-simulating ways. This is good news for people with cancer who do not respond to immune checkpoint inhibitors or develop resistance to them. The findings were published today in the journal Science. Learn More National Institute of Allergy and Infectious Diseases  |  National Institutes of Health

---

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. Your subscription may be removed if you do not open our emails for a six-month period. 

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).

                           

---

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107